UNIGE document Scientific Article
previous document  unige:116075  next document
add to browser collection
Title

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

Authors
Wilcock, Gordon K
Gauthier, Serge
Jia, Jianping
Hardlund, Jiri H
Moebius, Hans J
Bentham, Peter
Kook, Karin A
show hidden authors show all authors [1 - 22]
Published in Journal of Alzheimer's Disease. 2018, vol. 61, no. 1, p. 435-457
Abstract LMTM is being developed as a treatment for AD based on inhibition of tau aggregation.
Keywords AgedAged, 80 and overAlzheimer Disease/diagnostic imaging/drug therapyAntipsychotic Agents/therapeutic useCohort StudiesDouble-Blind MethodFemaleHumansInternational CooperationMaleMental Status and Dementia TestsMethylene Blue/analogs & derivatives/therapeutic useMiddle AgedTreatment Outcome
Identifiers
PMID: 29154277
Full text
Article (Published version) (1.7 MB) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group Troubles de mémoire et maladie d'Alzeimer (935)
Citation
(ISO format)
WILCOCK, Gordon K et al. Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. In: Journal of Alzheimer's Disease, 2018, vol. 61, n° 1, p. 435-457. https://archive-ouverte.unige.ch/unige:116075

41 hits

0 download

Update

Deposited on : 2019-04-10

Export document
Format :
Citation style :